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Introduction
Ear is the most important sensory organ concerned with the perception 
of hearing. Infections are the leading causes of deafness worldwide. (CSOM 
Burden of illness and management WHO 2004).
CSOM is a chronic Suppurative inflammation of mucoperiosteal layer of 
the middle ear cleft  (Plate1). Incidence of CSOM higher in developing than 
developed countries particularly in India.  The global burden of illness from 
CSOM involutes 65-330 million individuals with draining ears, 60% of whom 
38-200 million suffer from significant hearing impairment CSOM accounts for 
28000 deaths and a disease burden of over 2 million disability adjusted life 
years. Over 90% of the burden is borne by countries in south East Asia (WHO 
2004) It  shows the importance of controlling the infections effectively by for 
preventing  the  hearing  loss  all  over  the  world.  In  developed  countries  the 
incidence of CSOM had come down to 0.04% of all cases of suppurative otitis  
media. In a rural area of India it was found to be 4.26%. Chronic suppurative 
otitis media is considered to be major problem in developing countries with 
relatively high mortality and morbidity (Glass cock et al; 1990). Pseudomonas 
aeruginosa is an opportunist  pathogen that can infect almost any body site 
given the right predisposing conditions.  
Pseudomonas  aeruginosa  is  a  significant  pathogen  among  gram-
negative  organisms  infecting  ear  (Brobby  Gwetal  ;  1987,  Brook  I  
et al., 1996).  Infections caused by pseudomonas aeruginosa are often severe 
and life threatening and are difficult to treat because of the limited susceptibility 
to anti microbial agents. (Carmeli; Y; et al ; 1999).
The problem of antibiotic resistance in Pseudomonas aeruginosa is on 
the increase. Accumulation of resistance after exposure to various antibiotics 
and  cross-resistant  among  agents  may  result  in  multidrug  resistant 
Pseudomonas aeruginosa.
Though chemical  have been used against  infections  from 17 th 
century  the  scientific  era  of  anti  microbial  agents  for  combating  infections 
started in the first decade of 20th century by paul Ehrlich based on the principle 
of 
1. Selective  Toxicity 
2. Specific  chemical  relationship between infective  agents and antibodies 
even though we could control the most of infections through antibiotics 
the  development  of  drug  resistance  was  noticed  along  side.  Bacteria 
started developing multi drug resistance though genetic and non genetic 
mechanisms because of the selective pressure posed by the antibiotic on 
there survival.  
In  recent  year  Pseudomonas  resistant  to  multi  drugs  including  
β-lactum  antibiotics  and  extended  spectrum  of  Cephalosporin  is  of  great 
concern  to  ENT surgeons.  Pseudomonas  aeruginosa  resists  β  lactum 
antibiotics  by  synthesising  β  lactamases.  These  enzymes  inactivate 
cephalosporins  by  hydrolyzing  the  amide  bond  of  the  β  lectum  ring.  The 
Subsequent  generation  of  cephalosporins  which  could  over  come  β 
lactamases  are  called  extended  spectrum of  cephalosporins  which  include 
oxyimino  β  lactum  like  Ceftazidime  and  cefotaxime.  Resistance  to  the 
antibiotics are by synthesis  of  extended spectrum of  β  lactamases (ESBL) 
which  are  plasmid  mediated,  these  enzymes  different  from  their  parent 
enzymes by only few amino acids portion but can hydrolyse extended section 
of cephalosporins.
Though  these  plasmid  mediated  β  lactamases  are  observed  in 
pseudomonas  areuginosa  isolates,  a  new  class  of  chromosomally  encode 
section  of  β  lactamases  also  reported.  These  enzymes  have  moderate 
hydrolysis  activity  for  oxacillin  but  high  activity  against  extended  spectrum 
cephalosporins cefotaxime and ceftazidime.
As  antibiotic  resistance  continues  to  escalate  and  speed  with  a 
vengeance in our environment, our complacency, remisistant of behaviour in 
the peresistence were in handling our greatest resource the "miracle drugs" is 
no  longer  acceptable.  Increasing  resistance  requires  us  to  manage  the 
infectious disease in a more ecologically conscious manner. It is necessary to 
promote the rational use of antibiotics.
So it is need of the hour to evaluate the multidrug resistant pseudomonas 
aeruginosa in chronic suppurative otitis media. Against this back ground we 
evaluate  the  multi  drug  resistant  among pseudomonas  aeruginosa  isolates 
from chronic suppurative otitis media.
As  Pseudomonas  aeruginosa  is  the  most  prevalent  gram  negative 
organism  in  CSOM.  Production  of  various  enzymes  by  them  may  require 
alteration  in  the  management  profile  of  gram-negative  chronic  Suppurative 
otitis media infection.
Hence we believe that our study will definitely enlight and advance in the 
management of multidrug resistant pseudomonas infection in middle ear and 
work towards reducing the morbidity and mortality  by which we can reduce the 
hearing loss in many patients residing in developing  countries like India.
AIMS & OBJECTIVES OF THE PRESENT STUDY
a) Isolation of aerobic causative  organisms from chronic suppurative 
otitis media. 
b) Identification of pseudomonas aeruginosa from chronic suppurative 
otitis meida and their characterization.
c) Determination  of  minimum  Inhibitory  concentration  of  selected 
expanded  3rd and  4th generation,   for  pseudomonas  aeruginosa 
isolation from CSOM.
d) Detection of group I inducible  β – Lactamase production by the test 
isolates and their prevalence.
e) Detection  of  extended  spectrum  of  β  –Lactamases  (ESBLs) 
producers  among  the  pseudomonas   aeruginosa  isolates  from 
CSOM and their prevalence.
f) To evaluate synergy effects of selected antibiotics.
g) Comparative  study  of  Multidrug  resistant  between  Pseudomonas 
aeruginosa and other isolates from CSOM.
h) To  isolate  plasmids  from  CSOM  strains  of  Multidrug  resistant 
pseudomonas aeruginosa.
Review of Literature
2.1 Chronic Suppurative otitis media
Ear is the most important sensory organ concerned with perception of 
sound. Infections of Ear are the leading causes of deafness in India.
Chronic suppurative otitis media is a persistent inflammation of middle 
ear  of  mastoid  cavity.  It  is  characterised  by  recurrent  or  persistent  ear 
discharge over 2 – 6 weeks through a perforation tympanic membrane (Plate 
2).  Typical  findings  also  include  thickened  granular  middle  ear  mucosa, 
mucosal polyp, and cholesteotoma with in the middle ear (Scott and brown 5 th 
edition, text book of otology). The incidence of chronic suppurative otitis media 
appears to depend socio economic factors such as poor living conditions, over 
crowding, poor hygiene and nutrition have been suggested as the basis for the 
wide spread prevalence of chronic suppurative otitis media in the developing 
countries like India. Chronic suppurative otitis media is traditionally classified 
into two main groups Tubo tympanic and attico antral diseases. Tubo tympanic 
disease was considered safe from complication while the attico antral disease 
was  considered  to  be  a  dangerous  and  unsafe  form  of  disease  in  which 
intracranial complications are possible.
The wide of microbes both aerobic and anaerobic present in chronic 
suppurative  otitis  media.  The types  of  aerobic  microbes isolated  in  chronic 
suppurative  otitis  media  are  pseudomonas,  proteus,  E.  Coli,  Klebsiella, 
staphylococcus  aureus  and  anaerobes  are  bacteroid  melanino  genicus,  B. 
Fragilis,  pepto  streptococcus  and  propionibacterium (Brobby  Gwetal;  1987. 
Brook I et al; 1996).
2.2 Pseudomonas aeruginosa
Pseudomonas aeruginosa are aerobic motile straight and slender gram-
negative bacilli range from 1-5 mm in length and 0.5 to 1mm in width. They use 
variety  of  carbohydrate,  alcohol  and  amino  acid  substrates  as  carbon  and 
energy  sources.  Although  they  are  able  to  survive  and  possibly  grow  at 
relatively  low  temperatures  (as  low as  4ºC)  they  are  mesophilic  (optimum 
temperatures for growth is between 30 to 37ºC) .
Pseudomonas  aeruginosa  can  be  grown  in  ordinary  medium  like 
nutrient agar. On nutrient agar the colonies are large, circular, flat with irregular 
spreading margins, The Colonies show metallic tinge and produce diffusible 
phenazin pigment when grown.
In Macconkey agar the organism grow as transparent, spreading non-
lactose fermenting colonies with metallic tinge. In broth the organism produces 
thick  surface  pellicle  while  growing  and  pigment  diffuses  from  surface  of 
medium.
Biochemically  pseudomonas aeruginosa behaves as a non-fermenter 
breaking down glucose and other sugars oxidatively, which can be detected in 
amino  sugar  media.  Prompt  oxidase  positivity,  citrate  utilization,  Pigment 
production, growth at 42ºC and non- fermenting reactions help in confirmation 
of this organism, they are widely present in nature. They have isolated from 
Soil, water, plants, hot tubs, whirl pools and hospital environments. Rarely they 
are part of normal flora in healthy individuals. The transmission is known to 
occur  through  ingestion  of  contaminate  food  and  water,  exposure  to 
contaminated  mediated  devices  and  solution,  introduction  by  penetrating 
wounds and person to person transmission.
Pseudomonas aeruginosa infections in the ear are an important public 
health  problem.  The  intrinsic  virulence  of  an  organism relates  its  ability  to 
invade tissue, resist host defense mechanisms and produce tissue damage. 
Disruption of normal ear surface predisposes the ear to microbial adherence 
invasion and infectivity.  Pseudomonas infection in  chronic  suppurative  otitis 
media (Tubo tympanic type) is the commonest disease, causing deafness.
2.3.  CEPHALOSPORINS
Some  cephalosporium  fungi  yield  antimicrobial  substances  called 
cephalosporins.  These  are  (β-lactam  compounds  with  a  nucleus  of  7-
aminocephlosporanic  acids,  instead  of  the  penicillins'  6-aminopenicillanic 
acid.  Natural  cephalosporins  have  low  antimicroibial  activity,  but  the 
attachment of various R side groups has resulted in the proliferation of an 
enormous  array  of  drugs  with  varying  pharmacologic  properties  and 
antimicrobial spectra and activity.
2.3.1  MECHANISM OF ACTION
The  mechanism of  action  of  cephalosporins  is  analogous  to  that  of 
penicillins:
 Binding  to  specific  PBPs  that  serve  as  drug  receptors  on 
bacteria 
 Inhibiting    cell    wall    synthesis    by    blocking               trans 
peptidation of peptidoglycon
 Activating autolytic enzymes in the cell wall that can   produce 
lesions resulting in bacterial death.
2.3.2 RESISTANT TO CEPHALOSPORINS
Resistant to cephalosporins can be attributed to: 
 Poor permeation of bacteria by the drug 
 Lack of PBP for a specific drug 
 Degradation of drug by β-lactamases
2.3.3 COMMONLY USED CEPHALOSPORINS
For  easy  reference,  cephalosporins  have  been  arranged  into  three 
major groups or generations. Many cephalosporins are mainly excreted by the 
kidney and may accumulate and induce toxicity in renal insufficiency.
2.3.4 FIRST GENERATION CEPHALOSPORINS
First   generation   cephalosporins   are   very   active   against   gram-
positive cocci except enterococci and methicillin resistant  Staphylococci  and 
meditatively active against some gram-negative rods-primarily E. coli, Proteus, 
and Klebsiella. Anaerobic cocci are often sensitive.
 (Example: Cefazolin, Cephalexin, Cephradine, Cefdraxil
2.3.5 SECOND GENERATION CEPHALOSPORINS
The second-generation cephalosporins are a heterogeneous group. All 
are  active  against  organisms  covered  by  first  generation  drugs  but  have 
extended  coverage  against  gram  negative  rods  including  Klebsiella, 
Enterobacter, and Proteus but not P. aerugirosa
 (Example: Cefamandole, Cefoxitin, Cefuroxime)
2.3.6 THIRD GENERATION CEPHALOSPORINS
Third generation cephalosporins have little activity against gram-positive 
cocci.   These   drugs   are   very   useful   in   the   management   of hospital  
acquired gram-negative bacterimia. 
(Example: Cefotaxime, Ceftazidime, Ceftriaxone)
2.3.7 FOURTH GENERATION CEPHALOSPORINS
Some new cephalosporins classified as fourth  generation drugs.  The 
new  agents  have  comparable  or  slightly  enhanced  activity  against  some 
enterobcateriaceae that are resistant to third generation cephalosporins. They 
are  not  active  against  P.  aeruginosa  that  are  resistant  to  third  generation 
drugs. 
(Example: Cefepime)
The significance of P. aeruginosa lies in its ability to develop resistance 
to  various  antibiotics  currently  used  in  clinical  practice,  in  particular  to 
extended spectrum  β-lactamases. Their resistance is mainly due to synergy 
between multi-drug efflux systems,  β-lactamases production, and low outer 
membrane  permeability  or  through  a  combination  of  multiple  unrelated 
resistance  mechanism.  Out  of  these  resistance  mechanisms  the  current 
research  is  on  production  of  β-lactamases  and  extended  spectrum  of  β-
lactamases.  β-lactams  account  for  approximately  50%  of  global  antibiotic 
consumption and this heavy usage exerts considerable selective pressure for 
resistance arising via production of β-lactamases.
β-lactamases are the commonest cause of bacterial resistance to β-lactam 
antimicrobial agents. Many β-lactamases are known, and at present there are 
about 190 types. Most function by a serine ester
2.4      CLASSIFICATION OF β -LACTAMASES
β-lactamases  have  been  classified  by  their  hydrolytic  spectrum, 
susceptibility to inhibitors, and whether they are encoded by the chromosome 
or by plasmids. Also whether cephaloridine is hydrolyzed more rapidly than 
benzylpenicillin, or vice versa, and on whether an enzyme is inactivated by 
cloxacillin,  clavulanate,  aztreonam,  or  p-chloromercuribenzoate.  Though 
various classification were put forward a major reorganization and an updated 
classification  of  β-lactamases was  proposed by Bush in  1995 (Bush  et  al, 
1995). The revised Bush scheme classifies  β-lactamases by their substrate 
preference among penicillin, oxacillin, carbenicillin, cephaloridine, expanded-
spectrum cephalosporins, and imipenem and by their susceptibility to inhibition 
by clavulanate.
Fig. 1. Action of a serine (β-lactamase.
The enzyme first associates noncovalently with the antibiotic to yield the 
noncovalent Michaelis complex. The β-lactam ring is then attacked by the free 
hydroxyl on the side chain of a scrine: residue at the active Site of the enzyme,  
yielding a covalent acyl  ester. Hydrolysis of the ester finally liberates active 
enzyme and the hydrolyzed, inactive drug. This mechanism is followed by β-
lactamases of molecular classes A, C, and D, but class B enzymes utilize a 
zinc ion to attack the [β-lactam ring. (Livermore, 1995).
β-lactamases are classified by sequence, was first proposed by Ambler 
(Ambler,  1980).  Such  classification  is  stable,  as  it  reflects  fundamental 
relationships  and  cannot  be  distorted  by  mutations.  Moreover,  sequence-
based classification has the beauty of simplicity, recognizing only four classes, 
designated A to D. Classes A, C, and D Comprise evolutionarily distinct groups 
of serine enzymes, and class B contains the zinc types.
At present, classes recognized in Bush's phenotypic classification and 
those defined in the molecular scheme, except that Bush's group 2d includes 
a few class A enzymes from actinomycetes as well as all the class D types 
from gram negative rods.
2.5 FREQUENCY OF ENZYME PRODUCTION
Frequencies  vary-hugely  among  countries,  hospitals,  unit  types,  and 
patient types. Resistance generally is most common where antibiotic usage is 
greatest  (Sanders  and  Sanders,  1992)  notably  in  intensive  care  units, 
hematology departments, and burns units, as well as in developing countries, 
where  medical  and  surgical  advances  often  outpace  infection  control. 
Conversely,  resistance  rates  often  are  very  low  in  the  general  wards  of 
community  hospitals  of  developed  countries.  Such  differences  are  easy  to 
rationalize in terms of the degree of selection pressure, as are high resistance 
rates in recalcitrant infections (e.g.,  P. aeruginosa in cystic fibrosis), in which 
bacteria are repeatedly exposed to antimicrobial agents. Rates of β-lactamase 
production also vary hugely in community-acquired pathogens from different 
geographic sources.
2.6      DEFINITION OF RESISTANCE
The effects of (β-lactamases on resistance sometimes are unequivocal. 
(β-lactamases reduce susceptibility without raising MICs above the breakpoint 
and,  similarly,  (β-lactamase  inhibitors  reduce  MICs  without  restoring  full 
susceptibility.  Susceptibility  and resistance can be defined on the  basis  of 
either biological or pharmacological criteria (Livermore, 1995).
Biological breakpoints view an organism as resistant if the observed MIC 
or inhibition zone falls outside the normal distribution of MICs or zones for 
isolates  without  specific  resistance  mechanisms;  (O'Brien,  1987;  Williams, 
1990)  pharmacological  breakpoints,  favored by the National  Committee for 
Clinical  Laboratory  Standards  (Villanova,  2000)  and the  British  Society  for 
Antimicrobial Chemotherapy (Jennifer, 2001), define resistance relative to the 
drug concentration achievable in vivo.
Biological analysis automatically gives significance to small reductions in 
susceptibility  and  allows  emerging  low-level  resistance  to  be  detected  and 
monitored, whereas pharmacological  breakpoints may demand tiny or huge 
MIC changes before an organism is deemed to be resistant. For example, the 
NCCLS (pharmacological) breakpoint for cefoxitin of 16 mg/ml is only double 
the  modal  MIC  for  typical  E.  coli  or  Bacteroides  isolates,  whereas  the 
breakpoint  for  cefotaxime  of  8  mg/ml  exceeds  the  MICs  for  typical 
enterobacteria by 50- to 100-fold.  Examples can be found to defend either 
basis of choosing breakpoints, and it is worth citing two contrasting examples. 
First,  many  extended-spectrum  TEM  p-lactamases  raise  the  MICs  of 
cefotaxime and other extended-spectrum cephalosporins for enterobacteria to 
only  1  to  4  mg/ml,  compared  with  0.03  mg/ml  for  isolates  without  these 
enzymes (Jorgensen  et  al,  1990) Although the MICs for the producers are 
below the NCCLS breakpoint, the organisms commonly prove resistant in vivo 
(Rice  et al,  1991). Such a situation is powerful ammunition to proponents of 
biological breakpoints, who can point' out that MICs for the enzyme producers 
were  32-  to  128-fold  above  the  normal  level.  On  the  other  hand,  N. 
gonorrhoeae  isolates which,  through impermeability and target  modification, 
are biologically resistant to penicillin (MICs of 0.25 to 1 mg/ml compared with 
0.008  mg/ml  for  fully  susceptible  isolates)  remain  susceptible  to  high-dose 
penicillin  in  vivo.  Here,  the  pharmacological  breakpoint  of  2  mg/ml  is 
defensible,  particularly  since  the  β-lactamase-producing  strains,  which  are 
unresponsive in vivo, tend to be more highly resistant, with MICs being around 
16 ug/ml.
This  review  will  indicate  several  instances  in  which  pharmacological 
breakpoints give a falsely optimistic picture of susceptibility for  β-lactamase 
producers and for which biological analysis is more appropriate, on the basis 
of clinical experience. Biological rather than pharmacological breakpoints must 
also be considered by anyone attempting to use antibiogram data to predict 
the resistance mechanisms present in clinical isolates. It should, however, be 
appreciated that biological breakpoints are easy to define when a susceptibility 
distribution is bimodal, with the MICs or zones for isolates with a β-lactamase 
(or other resistance mechanism) distinct  from those for isolates without the 
enzyme, but are harder to set when the possessors of the mechanism merely 
form the tail of a skewed normal distribution (Williams, 1990).  β-Lactamase-
inhibitor  combinations  present  a  particular  problem  in  this  regard,  as  the 
inhibitors reduce the MIC of their partner penicillins for β-lactamase producers 
but generally fail  to render the bacteria as susceptible as those without the 
enzyme (Livermore, 1993; sanders et al, 1988).
Some  β-lactamase  hyperproducers  are  resistant  to  inhibitor 
combinations,  but  the  zonea  or  MICs  for  these  organisms  do  not  form  a 
distinct distribution from those for organisms that have slightly less enzyme 
and that,  consequently,  are susceptible.  Pharmacological  analysis  allows a 
breakpoint to be drawn in these circumstances, although its positioning may 
be highly arguable, as has been the case with ticarcillin-clavulanate (Sanders 
etal, 1988).
2.7 CHROMOSOMAL  β -LACTAMASES  OF  PSEUDOMONAS 
AERUGINOSA
P.  aeruginosa  has  an  inducible  AmpC  enzyme,  similar  to  that  of 
Enterobacter  spp. As with  Enterobacter  spp., ampicillin and narrow-spectrum 
cephalosporins  are  labile  to  hydrolysis  and  induce  the  enzyme  strongly,  
destroying their own activity, whereas ureidopenicillins and extended-spectrum 
cephalosporins  are  labile  but  induce  weakly  and  so  are  active  against 
inducible strains but not against derepressed mutants (Livermore and Yang, 
1987). Carbapenems are strong inducers that are marginally labile (imipenem) 
(Livermore and Yang, 1987) or are effectively stable (meropenem) (Livermore 
and  Yang,  1989)  and  so  remain  active  irrespective  of  the  mode  of  (β-
lactamase lactamase expression. Differences from the  Enterobacter  system 
are (i) that carbenicillin is less affected by derepression in P. aeruginosa, with 
its MICs increasing from 32 to 128 mg/ml for inducible isolates to 64 to 256 
mg/ml  for  derepressed ones,  as against  from 1 to  2 mg/ml to  128 to  256 
mg/ml, respectively, for (β-lactamase-inducible and derepressed Enterobacter 
spp. (Livermore and Yang, 1989; yang et al, 1988); (ii) that the P. aeruginosa 
enzyme,  whether  inducible  or  derepressed,  gives  slight  protection  against 
imipenem, with MICs for producers being around 1 to 2 mg/ml compared with  
0.12  to  0.5  mg/ml  for  β-lactamase-deficient  laboratory  mutants  (Livermore, 
1992); and (iil) that derepression in  P. aeruginosa  is often only partial, such 
that the uninduced enzyme level is higher than is normal for the species but  
substantial inducibility is retained (Sanders and Sanders, 1992; Williams et al, 
1984), whereas derepression in Enterobacter spp.
Is  almost  always  total,  with  the  enzyme  being  manufactured 
constitutively.  P.  aeruginosa  strains segregate partially derepressed mutants 
at  rates  of  ca.  1027,  but  totally  derepressed mutants occur  at  frequencies 
below  1029,  whereas  Enterobacter  spp.  segregate  totally  derepressed 
mutants  at  frequencies  of  1025  to  1027.  The  resistance  of  partially 
derepressed  isolates  mirrors  the  amount  of  enzyme  produced  without 
induction; even a small degree of derepression compromises ureidopenicillins, 
whereas  only  total  derepression  noticeably  compromises  cefepime  and 
carbenicillm (Williams et al, 1984).
Selection of totally or partially derepressed mutants can occur during 
antipseudomonal  therapy  with  labile  weak  inducers.  Ureidopenicillins  and 
piperacillin, as well as extended spectrum cephalosporins, have been widely 
reported to select for these mutants in P.  aeruginosa  infections (Livermore, 
1987), whereas selection of derepressed enterobacteria is predominantly by 
cephalosporins. Overall,  however,  selection of derepressed mutants is rarer 
with P. aeruginosa than with  Enterobacter spp. and C. freundii,  except under 
the specialized conditions of the lungs of patients with cystic fibrosis. Evolution 
during  therapy  from  inducible  through  partially  derepressed  to  totally 
derepressed  has  been  reported  (Shannon  et  al,  1982),  but  it  is  unclear 
whether this is the invariable pattern or whether total derepression can also 
arise directly from inducibility.
2.8 PLASMID  MEDIATED  AND  OTHER  SECONDARY  
β -LACTAMASES  OF  NON  FASTIDIOUS  GRAM-NEGATIVE 
BACTERIA
2.8.1 DISTRIBUTION AND DIVERSITY:
Over  75  different  plasmid-mediated  β-lactamases  have  been 
recorded in gram-negative bacilli, (Bush et al., 1995) and numerous surveys of 
their frequency have been undertaken. The commonest of these enzymes in 
enterobacteria  is  TEM-1,  which  is  responsible  for  most  of  the  ampicillin 
resistance now seen in about 50% of E.  coli  isolates (Sanders and Sanders, 
1992).  TEM-2,  SHV-1,  and  OXA-1  p-lactamases  also  are  widespread  in 
enterobacteria, although they are much rarer than TEM-1, and numerous other 
types have been seen in occasional isolates.
Secondary β-lactamases in P. aeruginosa have been reported widely but 
are much rarer than in enterobacteria. Thus, multicenter surveys in the United 
Kingdom found secondary β-lactamases in only 2.5% of 1,866 P. aeruginosa 
isolates collected in 1982 (Williams et al, 1984), incidence rates of 13 and 7% 
have been reported from France (Thabaut  et  al,  1985)  and Spain (Tirado, 
1986), respectively, but these last studies are over 10 years old. Aside from 
their  scarcity,  the  other  characteristic  of  secondary  β-lactamases  in  P. 
aeruginosa  is their diversity.  PSE-1 and PSE-4 enzymes predominate in P. 
aeruginosa  (Thabaut  et al,  1985; Tirado, 1986; Williams et  al,  1984), largely 
because of the clonal selection of producers rather than because of plasmid 
spread (Livermore et al, 1985; Pitt et al, 1990). In addition, however, numerous 
OXA  types  have  been  recorded  in  P.  aeruginosa,  as  have  various  more 
obscure types such as NPS-1 and LCR-1. TEM and SHV types do occur but  
are rare, in contrast to their predominance in enterobacteria.
The classical TEM-1, TEM-2, SHV-1, OXA-1, PSE-1, PSE-4 enzymes 
have minimal activity against newer cephalosporins, other than cefamandole 
and cefoperazone (O'Callaghan, 1979). In the past 10 years, however, there 
has  been  increasing  emergence  of  "extended-spectrum"  β-lactamases 
(ESBLs), which attacks many newer cephems and monobactams as well as 
narrow-spectrum cephalosporins and anti-gram-negative-bacterium penicillins 
(Jacoby and Medeiros,  1991 and Philippon et  al.,  1989).  Most  ESBLs are 
mutants  of  TEM-1,  TEM-2,  and  SHV-1,  with  1-  to  4-amino-acid  sequence 
substitutions.  These  changes,  amounting  to  less  than  2%  of  the  protein 
sequence, sufficiently remodel the enzyme active site to allow attack on most 
or all aminothiazolyl cephalosporins.
Over 25 different TEM and SHV variants have been claimed and are 
numbered TEM-3 to TEM-27 and SHV-2 to SHV-7. They are commonest in 
klebsiellae but also occur in other enterobacteria. The first major outbreak due 
to producers, specifically isolates with TEM-3  β-lactamase, occurred around 
Clermont-Ferrand in 1985 to 1987 (Petit et al., 1990) and was soon followed 
by outbreaks elsewhere in France (Jacoby and Medeiros, 1991).
TEM-3   seems commonest in France   (Petit   et al, 1990; Philippon, 
1989),  whereas  TEM-10,  TEM-12,  and  TEM-26  predominate  in  the  United 
States (Bradford  et al,  1994; Naumouski  et al,  1992; Rice  et al,  1993). SHV 
variants are also important worldwide. SHV-2 and SHV-5 enzymes have each 
been recorded in at least five countries (Jacoby and Medeiros, 1991), with the 
latter type widespread in Greece (Gianneli et al, 1994). A single serotype K25 
K. pneumoniae  strain with SHV-4  β-lactamase has, been transferred among 
many hospitals in France (Alert et al, 1994).
Other  ESBLs  besides  TEM  and  SHV  derivatives  are  emerging,  but 
these  presently  are  very  rare.  They  include  representatives  of  all  four 
molecular  classes.  Yet  another  recent  development  is  the  emergence  of 
mutants  of  TEM  and  SHV  (3-lactamases  that  lack  ESBL  activity  but  are 
resistant to inhibition by clavulanate and penicilianic acid sulfones.
It should be emphasized that the dissemination of plasmid mediated (3-
lactamases  in  gram-negative  bacteria  is  very  recent.  
TEM-1 enzyme was first reported from a single E. coli isolate in 1965, and the 
earliest known ESBLs date from 1982 to 1983 (Kliebe et al, 1985). There can 
be few examples of faster evolution than the spread of these enzymes.
2.9      EXTENDED-SPECTRUM TEM AND SHV β -LACTAMASES
The most notable feature of these enzymes, distinguishing them from 
their TEM-1, TEM-2, and SHV parent types, is their ability to attack extended-
spectrum  cephalosporins  and  monobactams,  as  well  
as  narrow-spectrum  cephalosporins  and  anti-gram-negative-  bacterium 
penicillins   (Jacoby  and  Medeiros,  1991;  Philippon  et  al.,  1989). 
Carbapenems and cephamycins are stable, as is temocillin. Ceftibuten 
is also stable to most types,  except to a few SHV derivatives (Jacoby and 
Carreras, 1990).
All the TEM- and SHV-derived ESBLs confer antibiograms that reflect 
this general  pattern of activity,  but  individual  enzymes vary in the levels of 
resistance they cause to different compounds. Some types, including TEM-3 
and SHV-2, give clear resistance (MIC, .16 mg/ml) to all extended-spectrum 
cephalosporins  and  to  aztreonam  (Jacoby  and  Carreras,  1990);  others, 
including the TEM-10 and TEM-26 types that currently predom- inate in the 
United States, give clear resistance to ceftazidime (MIC, >128 mg/ml) but raise 
the MICs of cefotaxime, ceftriaxone, cefpirome, and ceftizoxime to only around 
0.5 to 4 mg/ml (Jacoby and Carreras, 1990; Katsanis  et al,  -1994; Liu  et al., 
1992; Rice et al,  1993; Rice et al,  1990; Rice et al,  1991). TEM-12, which is 
the evolutionary ancestor of TEM-10 and TEM-26, is even feebler, generally 
raising the MICs of ceftazidime for E. coli and klebsiella isolates to only 4 to 8 
mg/ml and leaving- those of cefotaxime and .ceftriaxone at around 0.06 to 0.25 
mg/ml (Jacoby and Medeiros, 1991; Katsanis  et al,  1994; Rice  et al.,  1993; 
Rice et al, 1990), although giving greater resistance, especially to ceftazidime, 
in a porin-deficient strain (Weber et al, 1990). Producers of TEM-10, TEM-12, 
and TEM-26 enzyme types thus have biological resistance to the many newer 
cephalosporins, being up to 100-fold less susceptible than are strains without 
enzyme, but remain apparently susceptible at the breakpoints advocated by 
the NCCLS (8 to 16 mg/ml) (Katsanis et al, 1994; Rice et al,  1991). This can 
lead to serious interpretive problems. 
Various more or less complicated tests have been advocated, but the 
most practicable is simply to screen with ceftazidime, since virtually all ESBLs 
give clear resistance to this compound (Katsanis  et al,  1994). When isolates 
have reduced susceptibility to ceftazidime, double-disc tests can be used to 
screen for synergy between this compound and clavulanate, which is most 
conveniently available in amoxicillinclavulanate (20 plus 10, mg) discs. When 
the ceftazidime zone is expanded by the clavulanate, production of an ESBL is 
inferred. Such testing would be facilitated if discs combining ceftazidime and 
clavulanate were available, as one could simply compare the zones with and 
without inhibitor. E-test ellipseometers and Vitek cards with this combination 
are under  development,  and early  results  indicate that  they allow accurate 
detection of ESBL producers.
Carbapenems  are  stable  to  ESBLs,  and  imipenem  has  been  used 
successfully in vivo against many enzyme producers. Inhibitor combinations 
and cephamycins  may also overcome these enzymes,  but  their  efficacy is 
more controversial. Despite sensitivity of the enzymes to inhibition, MICs of 
clavulanate combinations and ampicillm-sulbactam often are high for ESBL 
producers  (Jacoby  and  Carreras,  1990;  Jacoby  and  Medeiros,  1991), 
presumably  because  high  levels  of  enzyme  are  present.  Piperacillin-
tazobactam seems a better prospect than other inhibitor combinations, at least 
against isolates with TEM derivatives, most of which are susceptible to the 
combination  at  16  plus  4  mg/ml  (Jacoby  and  Carreras,  1990).  Moreover, 
piperacillin-  tazobactam was  effective  against  a  K.  pneumoniae strain  with 
TEM-3  enzyme  in  a  rabbit  endocarditis  model,  whereas  unprotected 
piperacillin was inadequate (Leleu  et al,  1994).  Whether or not piperacillin-
tazobactam is a viable option against producers of SHV-derived ESBLs is less 
certain:  two  groups  (Bauernfiend,  1990;  Jacoby and  Carreras,  1990)  have 
reported  that  E.  coli  and  K.  pneumoniae  strains  and  transconjugants  with 
SHV-2,  SHV-3,  SHV-4,  and  SHV-5  enzymes  typically  were  resistant  to 
piperacillin- tazobactam, with MICs ranging upwards from 64 plus 4 mg/ml.
Cephamycins are stable to ESBLs, and the continued activity of these 
compounds, but not of other cephalosporins, facilitates laboratory recognition 
of ESBL producers (Jacoby and Carreras, 1990). Nevertheless, failures were 
reported  when  cefoxitin  was  used  against  ESBL  producers  and  were 
associated with selection of porin-deficient mutants (Pangon et al, 1989). It is 
unclear  whether  this  risk  would  arise  with  cefotetan or  moxalactam,  which 
share  the  stability  of  cefoxitin  to  ESBLs  but  have  10-  to  100-fold-greater 
antienterobacterial activity. Perhaps it is significant that there have been few 
reports  of  ESBL producers  in  Japan,  where  moxalactam has  long been a 
favored drug, and many reports from France and the United States, where 
cefotaxime, ceftriaxone, and ceftazidime have been preferred.
2.10   INHIBITOR-RESISTANT TEM MUTANTS
In addition to their ESBL derivatives, TEM--1 and TEM-2 [β-lactamases 
segregate mutants that have reduced affinity for clavulanate and the sulfones. 
Ten  variants  have  been  described  (Blasquez  et  al,  1993)  and,  to  add 
confusion,  have  been  numbered  variously  as  IRT  (inhibitor-resistant-TEM) 
types 1, 2, 3, etc.; as TRI (TEM, resistant to inhibitors) types 1, 2, 3, etc.; and 
as  TEM  types  30,  31,  32,  etc.!  Producer  strains  are  resistant  to  all  β-
lactamase-  inhibitor  combinations  but  are  less  resistant  than  isolates  with 
classical TEM-1 enzyme to narrow-spectrum cephalosporins and remain fully 
susceptible to extended-spectrum cephalosporins.
At present, resistance to inhibitor combinations is more often caused by 
high-level production of TEM-1 enzymes (Seetul singh  et al,  1991) than by 
these  mutants,  but  this  situation  may  change  as  more  potent  inhibitor 
combinations, such as piperacillin-tazobactam and cefoperazone-sulbactam, 
are increasingly used.
2.11  EXTENDED-SPECTRUM  SECONDARY  β -LACTAMASES  NOT 
RELATED TO TEM AND SHV.
Among extended-spectrum class A (3-lactamases that are not TEM and 
SHV derivatives are PER-1 (Danel et al, 1995; Nordmann et al, 1993), its close 
relative CTI-1 and MEN-1 (Bernard  et al,  1992). Each gives resistance to all 
cephalosporins,  aztreonam,  and  penicillins  but  spares  carbapenems  and 
cephamycins. CTI-1 and MEN-1 have been detected only in single isolates, but 
PER-1  appears  well  established  in  Turkey,  having  been  found  in  14  P. 
aeruginosa isolates collected over an 18-month period at an Ankara teaching 
hospital and in salmonellae from Istanbul (Danel et al,  1995). It has not been 
seen elsewhere, except in a P. aeruginosa isolate from a Turkish patient who 
was transferred to Paris (Nordmann et al,  1993). Its gene has been recorded 
on  at  least  three  different  plasmids  (Danel  et  al,  1995),  suggesting 
transposition. Isolates with PER-1 enzyme have a characteristic antibiogram, 
being highly resistant to ceftazidime (MIC, .256 nag/ml)-but very susceptible to 
ceftazidime- clavulanate (MIC, 1 to 4 mg/ml) and having only slightly reduced 
susceptibility to piperacillin (MIC, 8 to 16 mg/ml) as compared with typical  P. 
aeruginosa  isolates.  Other  exotic  class  A  enzymes  include  three  related 
carbapenemases, carbapenemases, Sme-1, Imi-1, and NMC-A, all  of which 
are encoded by nontransferable chromosomal inserts.  Sme-1 was from two 
Serratia marcescens isolates obtained in London in 1982 (Naas et al,  1994); 
NMC-A  was  from  a  single  B.  cloacae  isolate  obtained  in  Paris  in  1990 
(Nordmann  et  al,  1993).  Each  attacks  and  gives  resistance  to  penicillins, 
aztreonam, and carbapenems, with imipenem being compromised more than 
meropenem.
Aminothiazolyl cephalosporins are largely spared, and the enzymes are 
subject to inhibition by clavulanate. 
Plasmid-encoded class C enzymes have been reported from klebsiellae 
and E. coli isolates and represent cases where the chromosomal β-lactarnase 
genes  of  Enterobacter  spp.  and  C.  freundii  have  escaped  on 
extrachromosomal  elements.  The  first  claim  of  a  plasmid-mediated  AmpC 
enzyme  dates  from  1976  (Bobrowski  et  al.,  1976),  but  the  strain  and  its 
putative transconjugant were subsequently lost. Since 1989, however, several  
plasmid-encoded AmpC enzymes  have been documented,  including  MIR-1 
from  U.S.  isolates  (Papanicolaou  et  al,  1990),  CMY-2  from  South  Korea 
(Bauernfiend,  1989)  BIL-1  from Pakistan  (Payne  et  al,  1992),  FOX-1 from 
Argentina (Leiza  et al,  1994), LAT-1 from Greece (Tzouvelakis  et al,  1993), 
FEC-1 (Matsumoto et al, 1988) and MOX-1 (Horii et al, 1993) from Japan, and 
CMY-3  from  the  United  Kingdom  (Jenks  et  al,  1995).  Producers  have 
antibiograms  resembling  those  of  derepressed  Enterobacter  strains,  with 
resistance to all  β-lactams except carbapenems, temocillin, and mecillinam. 
Resistance usually is not reversed by clavulanate and sulbactam, although 
FEC-1  and  MOX-1  provide  exceptions  to  this  generalization.  The  lack  of 
susceptibility  to  cephamycins  and inhibitor  combinations distinguishes such 
producers from isolates with  TEM- and SHV derived ESBLs.  The fact  that 
producers of these enzymes have been reported from many different countries 
in a very brief period suggests that a real problem may be developing. Finally,  
extended-spectrum activity has been found in mutants of a class D enzyme, 
OXA-10 (PSE-2). One such mutant, OXA-11, has been reported by Hall et al 
(Hall et al., 1993). All are from P. aeruginosa isolates obtained at one hospital 
-in Ankara,  Turkey.  OXA-10 itself  has a broader spectrum than other OXA 
types,  giving  high-level  resistance  to  cefoperazone  and,  if  hyperproduced, 
causing  small  reductions  in  susceptibility  to  aztreonam,  cefotaxime,  and 
ceftriaxone.  Its  extended-spectrum  mutants  give  greater  resistance  to 
cefotaxime,  ceftriaxone,  and aztreonam and cause high-level  resistance to 
ceftazidime (MIC, 256 to 512 mg/ml), which is spared by OXA-10 itself. OXA-
10  and  its  derivatives  are  poorly  inhibited  by  clavulanate  or  sulfones. 
Carbapenems are stable to their activity.
2.12   TESTS FOR (β -LACTAMASE PRODUCTION
Many  tests  for  β-lactamase  production,  entailing  either  chromogenic 
reactions  or  detection  of  the  destruction  of  antibiotic  activity  have  been 
proposed.  The chromogenic methods are  faster  and more  convenient,  and 
they divide into those in which the hydrolysis of the β-lactam itself engenders a 
color change and those in which this change depends on a linked reaction.
In  the  former  group  are  nitrocefin  (O'Callaghan  et  al,  1972),  which 
changes from yellow to pink/red on hydrolysis, and 7-(thienyl-2-acetamido)-3-
[2-(4-N, N-dimethylaminophenylazo) pyridinium methyl]-3-cephem-4-carboxylic 
acid (PADAC), which changes from violet to yellow. Of these two, nitrocefin is 
the more readily available (albeit expensively) and can be used as a solution or 
as discs upon which test cultures are smeared. It is highly sensitive to most β-
lactamases, although false-negative results are a risk for /-/. influenzae isolates 
with  ROB-1  β-lactamase  and  for  staphylococci,  in  which  uninduced 
penicillinase  levels  are  often  inadequate  to  give  a  color  reaction.  These 
problems are minor, since ROB-1 enzyme is rare and  β-lactamase tests are 
rarely  performed  on  staphylococci.  Linked  detection  systems  include  the 
iodometric and acidimetric methods. The former depends on the fact that the 
hydrolysis  products  of  β-lactams  reduce  iodine  to  iodide;  consequently, 
decolorization of starch-iodine complex occurs if an isolate is a  β-lactamase 
producer but not if the enzyme is absent. Acidimetric tests depend on the fact  
that opening the β-lactam ring generates a free car'boxyl and that this acidity 
can turn bromocresol  purple from violet  to yellow in an unbuffered system. 
Acidimetric and iodometric tests can be performed with bacterial suspensions 
or on paper strips impregnated with the appropriate reagents. These methods 
are cheaper than nitrocefin and, given care, almost as sensitive, but they are 
more  prone  to  false-positive  results.  With  iodometric  tests,  such  errors 
probably  reflect  nonspecific  reaction  of  iodine  with  bacterial  proteins;  for 
acidimetric  tests,  false-positive  results  arise  if  the  inoculum or  the  distilled 
water used to moisten the test strip is slightly acidic. More generally,  these 
problems underscore the importance of performing parallel controls with known 
enzyme producers and nonproducers.
Such β-lactamase detection tests do not provide any information about 
what  type  of  β-lactamase  is  present.  Preliminary  typing  can,  however,  be 
achieved by running parallel  tests in the presence and absence of 0.1 mM 
clavulanate  and  0.1  mM  cloxacillin  (Williams  et  al,  1984);  most  class  A 
enzymes  are  inhibited  by  clavulanate  but  not  cloxacillin,  whereas  class  C 
enzymes give the opposite pattern; class B and most class D enzymes are 
inhibited by neither compound. These method's are, however, most useful for 
preliminary β-lactamase, typing in surveys rather than routine use. Their main 
limitation is that increasing numbers of isolates have multiple [3-lactamases 
and that these, obviously, can distort the inhibition 'patterns observed. Aside 
from  chromogenic  methods,  β-lactamase  production  may  be  detected  by 
various biological methods, which depend on the  β-lactamase produced by 
one organism allowing an indicator strain to grow. Examples include "clover 
leaf plates" and Masuda double-disc tests (Masuda et al,  1976). These tests 
are  extremely  sensitive  but  are  slow  and  tedious.  More  useful  biological 
methods  are  the  double-disc  tests  used  to  examine  for  synergy  between 
clavulanate and ceftazidime and, thereby, to detect ESBLs.
Materials and Methods
Isolation,  Screening and Characterisation of  pseudomonas aeruginosa 
from CSOM specimens
3.1 SPECIMENS
All  the  Ear  Swab  specimens  obtained  from  CSOM  patient  were 
processed  in  the  Department  of  microbiology  Government  medical  college 
hospital Coimbatore, South India from October 2005 to September 2006 were 
considered for the study, A total of 43 Pseudomonas aeruginosa isolates from 
chronic suppurative otitis media patients were cultured and they were stored 
as  suspensions  in  a  10%  (wt/vol)  skim  milk  solution  (STGG  medium) 
containing  10%  (Vol  /  Vol)  glycerol  at  80ºC  until  additional  tests  were 
performed.
COMPOSITION OF STGG MEDIUM
Skim milk powder - 2 gm
Triptycase soy broth - 3 gm
Glucose - 0.5 gm
Glycerol - 10ml
Distilled water  - 100ml.
3.2 SPECIMEN COLLECTION 
The Bacteriological cultures were obtained from CSOM patients as per 
standard procedure.  All  the exudates and necrotic materials  were removed 
from the external auditory canal using sterile cotton moist swab. Single use 
minitip culture swabs were used to harvest middle ear micro flora under vision 
and  were  transported  two  Ear  swabs  to  the  laboratory  without  delay.  The 
status of the external auditory canal and tympanic membrane was inspected to 
determine the disease entities (ie  otitis  media).  Two Swabs were  collected 
from each  patient  and  one  was  used  to  spread  on  clean  glass  slide  and 
stained with Gram's Stain for immediate microscopic examination.
The other swab was inoculated immediately to blood Agar, chocolate 
Agar, Macconkey Agar, Potato dextrose Agar, Cetrimide Agar and Brain heart 
infusion broth for bacteria isolation. "C" shaped streaks in a row were made 
with  spatula  while  inoculating  solid  media  in  order  to  obtain  inoculums  in 
decreasing gradation.
3.3 INCLUSION CRITERIA
1) Recurrent or persistent ear discharge over 2-6 wks through a perforation 
of  tympanic  membrane  who  had  not  received  Topical  or  systemic 
antibiotic therapy for the previous five days
2) Patients age ranged from 1 month to 80 years
Their  pathogenic  potential  was  confirmed  by  correlating  with  clinical 
findings and repeat isolations.
3.4 EXCLUSION CRITERIA
1. Acute otitis media
2. Chronic otitis media with effusion
3. Cases having purely sanguineous or CSF otorrhoea.
4. Antibiotic therapy (Topical or systemic) with in previous five days.
3.5    SPECIMEN PROCESSING
The specimens were processed as per standard protocol (Forbes et al, 
1998; Sharma, 1988) for isolation of bacterial and fungal organisms.
3.6.1 GRAMS SMEAR FROM THE SPECIMENS AND CULTURE 
SMEAR PREPARATION
1. The clinical material ear swab was spread thinly and uniformly over a 
clean glass slide with the help of sterile inoculation loop.
2. Smears from liquid cultures were made by spreading a loopful of the 
culture on a slide.
3. Smears from culture on solid media were prepared by emulsifying the 
colonies in a drop of saline placed on the slide and spread over thinly.
4. Smear was allowed to dry in air and then heat fixed by gently passing 
over a flame once or twice.
3.6.2 GRAM STAINING (Plate 3)
1. The heat fixed smear was flooded with crystal  violet and kept for 60 
seconds.
2. The  stain  was  poured off.  Then the  smear  was  washed  with  sterile 
distilled water and covered with Gram's iodine for 60 seconds.
3. Again the smear was washed with distilled water and decolorized with 
Acetone-alcohol mixture for not more than 10 seconds.
4. The smear was washed with  distilled water and counter stained with 
carbol fuschin for 30 seconds.
5. Then the smear was again washed with  distilled water,  air-dried and 
observation was made under oil immersion (100x).
REAGENTS:
PRIMARY STAIN:
Crystal violet - 10 gm
Absolute alcohol - 100 ml
Distilled water - 1 litre 
MORDANT:
Iodine - 10 gm
Potassium iodide - 20 gm
Distilled water - 1 litre
DECOLOURIZER: ACETONE-ALCOHOL MIXTURE
Acetone - 50 ml
95% ethanol - 50 ml
COUNTER STAIN:
Carbol fuschin strong     - 100     ml
Distilled water - 1 litre
3.7 MEDIA INOCULATION AND INCUBATION
The following media were included for isolation of the organisms; Blood 
agar, Chocolate agar,  MacConkey agar, nutrient agar, cetrimide agar, brain 
heart infusion broth and Potato Dextrose Agar.
All  the plates and liquid media were incubated overnight at  37'  C and 
plates were observed bacterial growth (Plate 5, 6). Plates showing confluent 
growth in more than one media simultaneously were considered for the study.  
Psudomonas  aeruginosa  colonies  produced  a  yellow  green  pigment  in 
cetrimide agar (Plate 7). The inoculated Potato Dextrose Agar was incubated 
at 27' C for fungal isolation.
MEDIUM COMPOSITION
TRYPTOSE BLOOD AGAR
Tryptose - 10 g
Beef extract - 3 g
Yeast extract         -      3 g
Sodium chloride      . - 5 g
Agar - 15 g
Distilled water - 1 litre
pH - 7.1
The medium was sterilized and allowed to cool to 45ºC and aspetically 
added 5% defibrinated sheep blood. Mixed thoroughly and poured into sterile 
Petri plates and stored in refrigerator.  
CHOCOLATE AGAR
Tryptose  blood  agar  medium  was  prepared  and  cooled  to  45°C,  
to which 5% blood was added, mixed thoroughly and was heated in a water 
bath at 80°C until the medium got a 'chocolate' colour. The medium was then 
poured into sterile petri plates and stored in refrigerator.
MacConkey AGAR
Peptic digest of animal tissue - 17 g
Protease peptone - 3 g
Lactose - 10 g
Bile salts - 1.5 g
Sodium chloride - 5  g
Neutral red     - 0.03 g
Agar  - 15 g
Distilled water  - 1 litre
pH  - 7.1
POTATO DEXTROSE AGAR
Potatoes infusion from - 300 g
Dextrose - 5.5 g
Agar - 15 g
pH - 5.6
NUTRIENT AGAR 
Peptic digest of animal tissue - 5 gm
Beef extract - 1.5 gm
Yeast extract - 1.5 gm
Sodium chloride - 5 gm
Agar - 15 gm
Distilled water - 1 litre
pH - 7.4
3.8    BIOCHEMICAL CONFIRMATION
The  confirmation  of  P.  aeruginosa  was  based  upon  production  of 
characteristic pigments (blue and green) (Plate 4). Additional biochemical tests 
used to identify P. aeruginosa included: Catalase, oxidase, Motility, oxidation 
of glucose on OF-medium, and growth in cetrimide agar (Forbes et al, 1998; 
Collee, 1996).
MOTILITY TEST: HANGING DROP PREPARATION
1. The  motility  of  the  organism  was  studied  using  hanging  drop 
preparation.
2. A concave slide was taken and soft petroleum jelly was applied to the 
surface of the slide encircling the convexity.
3. A Cover slip was taken and a drop of liquid culture was placed on the 
center of cover slip.
4. The cover slip was inverted over the cover slip in such a way that the 
cover slip got adhered to the slide.
5. Then the slide was placed on the mechanical stage of microscope with 
the organisms were tested for motility first under low-power objective 
and then with high power objective. 
CATALASE TEST
1. A small amount of over night culture was transferred on to the clean 
glass slide with a sterile wooden stick.
2. Immediately a drop of 3% hydrogen peroxide was placed onto a portion 
of a colony on the slide.
3. Evolution  of bubbles  from  the  colony was  considered  as  a positive 
test.
REAGENT: 3% HYDROGEN PEROXIDE
30% Hydrogen peroxide solution was diluted to have a concentration of 
3%.
OXIDASE TEST (Plate 8)
A small portion of colony was removed with wooden stick and rubbed 
with the growth on filter paper containing oxidase reagent.
REAGENT: 1% TETRAMETHYL-P-PHENYLENE-DIAMINE 
DIHYDROCHLORIDE
Whatman No.  1  filter  papers were  soaked in  a  freshly prepared 1% 
tetramethyl-p-phenylene-diamine dihydrochloride. After 30 seconds the strips 
were freeze dried and stored in a dark bottle tightly.
OXIDATION OF CARBOHYDRATE TEST 
MEDIUM
Peptone - 2.0 g
Sodium chloride - 5.0 g
Dipotssium hydrogen phosphate - 0.3 g
Bromothymol blue
(1% aqueous solution) - 3 ml
Agar                                                   - 3 g
Distilled water                                   - 1 litre
The pH was adjusted to 7.1 before adding bromothymol blue and the 
medium was  sterilized in  flask  at  121°C for  15  minutes.  The carbohydrate 
(glucose)  to  be  added was  sterilized  separately  and  added to  give  a  final 
concentration of 1%. The medium was then tubed to a depth of about 4cm. 
Medium was  inoculated  by  stabbing and  incubated  at  37°C.  Changing  the 
colour of the medium begins at the surface and gradually extends downwards 
was considered as positive oxidation reaction.
CETRIMIDE AGAR
Pancreatic digest of gelatin - 20 g
Magnesium chloride - 1.4 g
Potassium sulphate - 10 g
Cetrimide - 0.3 g
Agar - 15 g
Distilled water - 1 litre
pH - 7.2
3.9 MINIMUM INHIBITORY CONCENTRATION (Plate 10) 
DETERMINATIONS
3.9.1 ANTIMICROBIAL AGENTS
Antibiotics gradient strips (E: test) agar inoculation technique was used 
to determine the MIC. Himedia Hicomb MIC test strips were used in this study.  
Which is based on an innovative antimicrobial gradient provides precise and 
accurate assessment of antimicrobial activity against both fastidious and non-
fastidious microorganisms.
3.9.2 PRICIPLE AND INTERPRETATION 
The  antibiotic  gradient  is  created  on  the  strip  by  applying  different 
concentrations of antibiotics in repeated ways of an increasing number of small  
dots.  When  applied  to  the  agar  surface,  the  antibiotic  diffuses  in  to  the 
surrounding medium in high to low amounts from one end of the strips to the 
other. The gradient remains stable after diffusion and the Zone of inhibition 
created takes the form of ellipse. The MIC is read only on the side of the comb 
at the point where the zone edge meets the strip edge.
3.9.3 TECHNIQUE OF HICOMB MIC TEST 
Muller  –  Hinton  agar  was  prepared  and  sterilised  at  121ºcfor  15 
minutes. The pH of the each batch of Muller – Hinton agar was checked when 
the medium was prepared. Then medium allowed to cool to 45 to 50ºc in a 
water bath, The plates were poured to a depth of 4mm as quickly as possible 
to  prevent  cooling and partial  solidification in  the Container.  The agar  was 
allowed to solidify at room temperature. After the plates are solidified some 
representative plates were incubated at 37ºC for 48 hours to check sterility.  
The remaining agar plates were refrigerated until  needed.  The plated were 
used after sterility check. The refrigerated plates were allowed to cool to get 
the room temperature before the use.
3.9.3 CONTROL PLATES.
Drug free plates prepared from the base medium were used as growth 
controls.
3.10. ANTI  MICROBIAL  CONCENTRATION  AND  INOCULAM 
PREPARATION   
MIC for  cefotaxime,  Ceftazidime was  determined by an antimicrobial 
gradient strips (E. test) agar inoculation technique on Muller – Hinton Agar. 
The gradient Concentration of Cefotaxime and ceftazidime is 240 120,60, 30, 
15, 10, 7.5, 5, 3, 1, .1, .01, 0.001µg/ml,. The Test inoculam was Prepared with  
an  over  night  growth  of  each  isolate,  which  was  adjusted  to  a  turbidity 
equivalent  to 0.5 McFarland standard, The test organism was inoculated in  
Muller – Hinton Agar  plate. The inoculam was allowed to dry for 5 minutes 
with lid in place. The Hicomb MIC strip was applied on agar surface with the 
MIC  scale  facing  down  wards.  Then  plates  were  incubated  at  37ºC  and 
examined after 24 hours.
 MULLER – HINTON AGAR
Beef infusion – 300 ml 
Casein Hydrolysate - 17.5 gm
Agar - 15 gm
Distilled water - 1 Litre
Final pH - 7.4
0.5 McFarland Standard solution
Barium Chloride 1 % Solution - 0.05
Sulfuric Acid 1% Solution - 9.95 Ml
3.11 INTERPRETATION OF RESULTS.
The zone of inhibition created takes the form of ellipse. The MIC was 
read only on the side of the Comb at the point where the zone edge meets 
strip edge.
Pseudomonas aeruginosa ATCC 27853 was used as a reference strain 
in every batch of MIC tests.
3.12 DETECTION OF GROUP I INDUCIBLE β -LACTAMASES 
(Plate 11)
 β -lactamases was investigated by disc approximation method ((Miles, 
1996; Qin, et al, 2004; Collee, 1996). Cefotaxime (30 ug) disc was placed at 
distances 25 and 20 mm,respectively from a central (center to center) from the 
cephoxitin (30 pg) disc on Muller-Hinton agar plate inoculated with the test  
organism, After overnight incubation, distinct flattening of the inhibitory zone 
around the ceftazidime disc on the side nearest to the cephoxitin disc was 
regarded as the presence of inducible β-lactamase.
3.13  DETECTION  OF  EXTENDED  SPECTRUM  p-LACTAMASE  (ESBL) 
ACTIVITY (Plate 12)
Strains were screened for-the presence of ESBLs by the double-disc 
synergy method (Miles, 1996). Three ceftazidime (30 ug) discs were placed at 
distances 20, 15, and 10 mm, respectively, from a central amoxicillin-clavulanic 
acid disc. The test result was considered positive when an enhancement of the 
inhibition.  zone  around  at  least  one  of  the  ceftazidime  disc  toward  the 
clavulanic-acid disc was observed as described by Bert (Bert et al, 2003).
3.14 INVESTIGATION OF SYNERGY EFFECTS OF ANTIBIOTIC 
COMBINATIONS (Plate 13)
The synergy effects of the antibiotic combinations against the selected 
isolates were examined by disc diffusion test (Miles, 1996; Mayer and Nagy, 
1999) Two discs, each containing one or other of the two tested antibiotics, 
were placed at a distance of about 20 mm from each other on top of a P.  
aeruginosa isolate-covered agar plate. Synergy was considered to occur when 
there  was  a  well-observed  change (>2  mm) in  the  zone  of  inhibition.  The 
synergy was classified as weak when a change <2 mm was observed in the 
zone of inhibition (Mayer and Nagy, 1999).
3.15   PLASMID DNA ISOLATION
This procedure was  used to  extract  plasmid DNA from bacterial  cell 
suspensions  and was  based on the  alkaline  lysis  procedure  developed by 
Birnboim and Doly (Nucleic Acids Research 7:1513, 1979).
1.  Sterile 1.5 mL micro centrifuge tubes were labeled and 1000 uL of the 
cell suspension was pipetted out from fresh culture into each tube.
2.    The caps were closed and the tubes were centrifuged at maximum 
speed for 20 s.
3.  The supernatant was discarded using a micropipette without disturbing 
the cell pellet.
4.      Then 100 uL of Buffer 1 was added to each tube and the cells were 
resuspended.
5.    Then 200 uL of Buffer 2 was added to each tube and the solutions 
were mixed by rapidly inverting the tubes for few times.
6.      Following this the tubes were kept in ice for 5 minutes.
7.      Then  150  uL  of  ice-cold  Buffer  3  was  added  to  each  tube.  
The  caps  were  closed  and  the  solutions  were  mixed  by  rapidly 
inverting the tubes for few times. A white precipitate was formed.
8.  The tubes were kept in ice for 5 minutes
9.     Then tubes were centrifuged at a maximum speed for 5 minutes. After 
the centrifugation, the supernatants were transferred into clean 1.5 mL 
tubes, without disturbing the precipitate. The pellet was discarded and 
the supernatants were kept separately.
10.    To  each  tube  of  supernatant  an  equal  volume (about  400  μ L)  of 
isopropanol was added for precipitating the nucleic acids. The caps 
were closed and the solutions mixed vigorously. The tubes were kept 
at room temperature for 2 minutes and centrifuged at maximum speed 
for 5 minutes.
11. Then 200 μ L of absolute ethanol was added to each tube and mixed 
thoroughly.
12.    Then the tubes were centrifuged at a maximum speed for 2-3 minutes.
13. The  supernatant  was  carefully  removed  and  discarded.  The  tubes 
were  placed  in  the  fume  hood  with  the  caps  open  for  
15-20 minutes to dry off the last traces of ethanol.
14.    After drying the ethanol 20 μ L of TE buffer was added and the pellet 
was dissolved.
15.    In the end, tubes were labeled and stored it in the freezer for plasmid 
profile.
REAGENT BUFFER 1:
50 mM Tris-HCl -  1.576 g
50mMEDTA                      -  3.7224 g
100 ug/mL RNase A          -   5 uL
Distilled water                    -   200 ml
pH8.0
BUFFER 2:
1% SDS  - 2.0 g
0.2 M NaOH - 1.6 g
Distilled water - 200 ml
BUFFER 3:
3.0 M Potassium Acetate - 16.78 g
pH 5.5
18 ml of acetic acid was made upto 54 ml with distilled water. Discarded
11 ml. To remaining 43 ml, 57 ml of 0.3M potassium was added.
3.16   AGAROSE GEL ELECTROPHORESIS (Plate 14)
1.  To resolve the plasmid DNA, agarose gel of 0.8%  concentration was 
used.
2.     0 ml 1 Ox TAE buffer was mixed with 90ml of distilled and then 0.4g of 
agarose was added.
3.      The  solution  was  boiled  and  cooled.  Then  10  μ l  (10mg/ml)'stock 
Ethidium bromide was added with the 100 ml agarose solution When it 
came down to bearable heat, it was poured into the blocks which had 
suitable comb fixed to it.
4.       After the polymerization, the comb was removed.
5.     The gel was placed inside the Electrophoretic tank and the buffer was 
added into it.
6.     30 μ L of the sample was mixed with 5 μ L of loading buffer and loaded in 
to the wells.
7.     The voltage was set at 100 milli Ampere.
When the dye was near end of the gel, the gel was removed.
8. The  gel  was  read  for  plasmids  and  documented  under  UV  Trans 
illumination with the help of gel documentation system.
REAGENT
10X TAE BUFFER
Tris base                  -          48.4 gram
Glacial acetic acid        -   11.42 ml
0,5 M EDTA                 -          20 ml
pH - 8.0
LOADING DYE (6X):
40% sucrose
0.01 mg of Bromophenol Blue powder
Distilled water
MARKERS
λ DNA - HIND - III and (£>x 174. DNA Hae III digests were used as marker 
DNA
Results
During the study period from October 2005 to September 2006 a total of 
110 Ear Swabs were collected from 100 Patients with CSOM attending ENT op 
Coimbatore  Medical  College  hospital  and  Ear  swabs  were  processed  in  the 
laboratory  of  microbiology  department  Coimbatore  Medical  College  Hospital 
Coimbatore.  Out  of  100 patients with  CSOM 10 patients were  suffering from 
bilateral  CSOM  (Fig.1).  About  114  Organisms  were  isolated  from  110 
specimens.  Among  110  specimens  105  numbers  showed  positive  cultures 
(95.45%) This study showed that most common isolates obtained from CSOM 
patients  were  pseudomonas  aeruginosa  (37.7%),  Staphylococcus  aureus 
(32.4%),  Proteus  sp  (12.2%),  Klebsiella  sp  (7.8%),  Coagulate  negative 
staphylococcus aureus (2.6%), Streptococcus pyogens (1.7%), E. Coli (0.8%), 
Moraxella catarrhalis (0.8%), Candida Sp (2.6%), Aspergillus (0.8%). In total of 
105 positive cultures 9 cultures showed mixed growth (Table 1). 
The Organisms in the mixed growth were pseudomonas aeruginoasa and 
staphylococcus aureus in 3 cultures, pseudomonas aeruginosa and proteus in 2 
cultures, pseudomonas aeruginosa and aspergillus in 1 culture, staphylococcus 
aureus and Candida species in 3 cultures. Fungal growth was seen in 3.4 % of 
total isolation. Pseudomonas aeruginosa grew in 43 cultures. The antibiogram 
patterns showed 23 isolates of pseudomonas aeruginosa which were multi drug 
resistant (Table 7, Plate 9) (ie resistant to more than one antibiotic) (53.48%), 
Staphylococcus aureus (32.43%) Klebsiella Sp (33.37) and 
TABLE - 1
Organisms Isolated in CSOM
S.No Name of the Organism No of isolated Percentage
1. Pseudomonas aeruginosa 47 37.7%
2. Staphylococcus aureus 37 32.4%
3. Proteus Sp 14 12.2%
4. Klebsiella Sp 9 7.8%
5. Coagulase Negative 
Staphylococcus aureus
3 2.6%
6. Escherichia coli 1 0.8%
7. Streptococcus pyogenes 2 1.7%
8. Moraxella Catarrhal is 1 0.8%
9. Candida Sp 3 2.6%
10. Aspergillous Sp 1 0.8
TABLE - 2
Age and Sex wise distribution of isolates in CSOM
Age
Sex
Male Female
1-12 (Paediatric) 14 5
13-20 7 9
21-30 10 21
31-40 7 10
41-50 2 4
51-60 3 3
60< 4 1
Total 47 53
Range 2 – 65 years 1 ½ - 63 years
Percentage 47 % 53 %
Mean 28.95 28.01
Median 27 26
proteus  species  (14.2%)  (Fig.  5)   Twenty  three  isolates  of  pseudomonas 
aeruginosa were resistant to cephalosporins. The antibiogram (Table 4, Fig. 4) 
for  pseudomonas also  showed the  sensitive  pattern  as  Gentamicin  46.5%, 
Amikacin  79.1% Tobramycin  46.5%,  Ciprofloxacin  46.5%,  ofloxacin  46.5%, 
Cefotaxime  46.5%,  Ceftazidime  88.4%,  Cefepime  86%,  meropenam  93 
piperacillin. 95.31%. Minimum inhibitory concentration was found out for all the 
43 strains of pseudomonas aeruginosa for cefotaxime  and ceftazidime by Hi 
Comb (E. Test) method (Table 5) By this method  21 (48.8 %) strains were 
found to  be  resistant  to  cefotaxime and 5  (11.6)  strains  were  found to  be 
resistant to ceftazidime.
Strains  showing  MIC  value  > 16  mg/l  were  considered  resistant  for 
Cefotaxime and ceftazidime (includes intermediate and resistant categories) 
(Villanova  2000).  In  the  present  study  21  Strains  showed  resistance  to 
Cefotaxim. Out of these 9 (42.85%) strains showed MIC  >  64/mg/L and 12 
(57.15%) strains showed ranges between 16-32 mg/L for Cefotaxime. When 
we  have tested MIC for  Ceftazidime (Total  Ceftazidime resistance strain  5 
(11.6%), 3 (60%) strains showed MIC > 32 mg/L and 2 (40%) strains showed 
MIC of > 16/L (Table 8). 
Production of inducible  β  lactamase was detected using double disc 
diffusion  (Disc  approximation)  (Gencer,  etal.,  2002;  Miles,  1996)  test  for 
strains;  which  were  susceptible  to  cephalosporins.  It  was  observed that  20 
(43.5%) isolates  were  sensitive  to  cephalosporins  with  a  zone of  inhibition 
falling above 22 mm diameter. Out  of  these 
TABLE - 3
Age and sex wise distribution of pseudomonas aeruginosa
Age
Sex
Male Female
1-12 (Paediatric) 5 1
13-20 3 1
21-30 6 11
31-40 2 6
41-50 1 2
51-60 0 2
60< 2 1
Total 19 24
Range 3- 65 years 11-63 years
Percentage 44.18 54.82
Mean 25.42 33.83
Median 25 29.5
20 strains 8 (40%)were found to produce β- lactamases when induced with a 
distance of 25mm between two discs (Cefoxitin and Cefotaxime). By reducing 
the disc distance by 5mm all strains were induced to produce β- lactamases 
(Table 9).
By using double disc diffusion test,  extended spectrum  β-lactamases 
were detected in 23 Strains (Table 8). Which were resistant as per zone of 
inhibition. When the two discs (Clavulanic acid and cefotaxime) were 25mm 
apart.  Presence  of  ESBLs  was  detected  in  one  (4.3%)  isolate.  When  we 
reduced  the  distance  to  15mm  8  (34.7%)  strains  were  found  to  produce 
ESBLs.  At  10mm  disc  approximation,  
18 (78.2%) Strains.  By this method we found out that 1 (4.35) strain produced 
only one type of ESBLs and 18 (78.2%) strains produced more than one type  
of ESBLs and 4 (17.3%) strains did not produce ESBLs. The mechanism of 
resistance may be other than production of ESBLs in these strains.
The evaluation of the frequency of the synergic effects of the antibiotic 
combination was tested by the disc diffusion method. Amikacin and oflaxacin 
when combined with cefotaxime exhibited an expressed synergic effect (Well 
characterised change of > 2 mm in the in inhibition zone) in 15 (34.9%) and 14 
(32.5%) isolates. weak synergic change of < 2 mm in the inhibition zone was 
observed  in  6  (13.9%)  and  7  (16.3%)  isolates.  No  synergy,  no  change 
observed in the inhibition zone (Mayer and Nagy, 1999) in 22 (51.2%) and 22 
(51.2%) isolates (Table 10). 
TABLE - 4
Antibiotic  susceptibility  testing  by  Muller  Hinton  Agar  disc  diffusion 
methods.
S. No Name of the 
Antibiotics
No (7)  us 
Sensitive
No (%) of Percentage 
Resistance
1 Gentamicin 20 (46.5) 23 (53.5)
2 Amikacin 3 (79.1) 9 (20.9)
3 Tobramycin 20 (46.5) 23 (53.5)
4 Ciprofloxacin 20 (46.5) 23 (53.5)
5 Ofloxacin 20 (46.5) 23 (53.5)
6 Cefotaxime 20 (46.5) 23 (53.5)
7 Ceftazidime 38 (88.4) 5 (11.6)
8 Cefepime 37 (86) 6 (14)
9 meropenam 40 (93) 3 (7)
10 Piperaccillin 41 (95.34) 2 (4.66)
TABLE - 5
MICS of  Selected cephalosporins against  43-pseudomonas aeruginosa 
isolates from CSOM
Isolate
MICS of Antibiotics  (Break point of Resistance in 
Mg/L)
Cefotaxime (> 64) Ceftazidime > 32)
1 3 0.5
2 64 5
3 16 1
4 7.5 5
5 7.5 1
6 7.5 3
7 240 120
8 16 1
9 32 5
10 32 5
11 5 0.5
12 16 1
13 60 3
14 7.5 0.5
15 32 3
16 32 1
17 30 16
18 7.5 0.5
19 7.5 5
20 16 5
21 120 2
22 32 3
23 7.5 2
24 5 1
25 16 1
26 120 1
27 7.5 5
28 240 10
29 60 16
30 3 0.5
31 5 0.5
32 3 1
33 4 0.5
34 7.5 64
35 7.5 2
36 32 5
37 7.5 32
38 5 0.5
39 60 3
40 3 1
41 7.5 1
42 120 3
43 10 7.5
TABLE - 6
Age wise distribution of multidrug resistance pseudomonas aeruginosa
Age
No of PA 
isolated
No of MDR PA 
isolates
Percentage of 
MDR PA
1-12 (Pediatric) 6 3 50
13-20 4 2 50
21-30 17 8 47.05
31-40 8 3 37.50
41-50 3 2 66.6
51-60 2 2 100
60< 3 3 100
Total 43 23 53.48
TABLE - 7
Comparison of multidrug resistant in different isolates
S. No Name of the 
organisms
Total Number 
of isolates
No of MDR 
Isolates
Percentage
1. Pseudomonas 
aeruginosa
43 20 53.48
2. Staphylococcus 
aureus
37 12 32.4
3. Proteus Sp 14 2 14.3
4. Klebsiella Sp 9 3 33.3
5. Cons 3 Nil 0
6. Streptococcus 
Pyogens
2 Nil 0
7. Escherichia  coli 1 Nil 0
8. Moraxella 
Catarrhalis
1 Nil 0
TABLE - 8
Detection of extended spectrum β  - Lactamases by double disc synergy 
method (Total Resistant Strains 23)
Various disc distances 
between clavulanic acid and 
cefotaxime
No (%) of 
Positive No. (%) of Negative
25mm 1 (4.4) 22 (95.6)
20 mm 1 (4.4) 22 (95.6)
15 mm 8 (34.7) 15 (65.3)
10 mm 18 (78.3) 5 (21.7)
TABLE - 9
Detection of inducible B – Lactoamases by disc approximation method 
(Total sensitive strain 20)
Various disc distances 
between cefoxitin and 
cefotaxime
No (%)  of positive No (%) of Negative
25mm 8 (40%) 12 (60%)
20mm 20 (100) 0
TABLE - 10
Synergy  effects  of  combinations  of  Aminoglycosides  and 
fluroquinolones with third generation cephalosporins
Combination
No (%) of 
effective 
synergy
No (%) of weak 
synergy
No (%) of   No 
Synergy
Amikacine + 
Cefotaxime
15 (34.9) 6 (13.9) 22 (51.2)
Amikacine + 
Ceftazidime
16 (37.2) 7 (16.3) 20 (46.5)
Ofloxacin + 
Cefotaxime
14 (32.5) 7 (16.3) 22 (51.2)
Ofloxacine + 
Ceftazidime
16 (37.2) 6 (13.9) 21 (42.9)
TABLE - 11
Distribution of Pseudomonas isolates in different group of population.
Population No of Pseudomonas 
isolated
Percentage.
Agricultural 15 34.8
Construction 8 18.7
Pre School 1 2.4
School 8 18.7
College 2 4.6
Employee 5 11.6
House wife 1 2.4
Others 3 6.9
When  the  combinations  of  Amikacin  and  ofloxacin  with  Ceftazidime 
were tested by this method, synergy was observed in 23 (53%) isolates. The 
epidemiological analysis of the patients revealed the following details. Aerobic 
bacterial  isolates in middle ear infections did not show any sex predilection 
though the females were marginally more effected (53%) when compared to 
male 47% (Table 2, Fig. 2). In pseudomonas isolation from middle ear infection 
was more in females (55.8%) as in the Bacterial isolates from CSOM (Table 3). 
Common side of the CSOM infection was52% Left side, 38% Right side and 
10% in both side.
Chronic suppurative otitis media infections by pseudomonas aeruginosa 
were seen in all age groups. The frequency of infection varied in different age 
group with more cases in 21-40 years age group (Table 6, Fig. 3). The analysis 
showed bimodal distribution of cases in which lower incidences were noted in 
0-20  and  41-50  age  group  and  higher  incidences  in  21-40and  50-80  age 
group.  Multidrug  resistant  pseudomonas  infection  in  middle  ear  was  most 
commonly seen in middle age group and older age group. Most of the patients 
affected were agricultural workers (34.8%) (Table 11). The other major working 
group was construction workers  18.7% followed by school  children.  18.7%. 
The  other  groups  were  least  affected  (Pre  School,  employees,  college 
students, House wives and others).
Resistant plasmid isolation was done in all  ESBLs positive strains by 
alkaline lysis method developed by Birn boim and Doly. It was observed that 
plasmids were present in all ESBL positive strains.
Discussion
Chronic  suppurative  otitis  media  is  considered  to  be  major  health 
problem in the developing world with a relatively high morbidity and mortality. 
The  overall  prevalence  of  CSOM in  these  countries  ranges  from 5  -10  % 
(ManiJJ etal : 1987)). About 50% of brain absesses are otogenic in origin with  
a mortality rate of 50 -75% (Sulla et al 1989). The bacterial pathogens mainly 
involved  are  pseudomonas  aeruginosa,  staphylococcus  aureus,  proteus  sp 
and klebsiella sp. Infections lead among the causes of deafness and much 
importance to be given because of the morbidity they cause and also because 
of the increasing antibiotic resistance among bacterial isolates. It is becoming 
increasingly  difficulty  to  control  chronic  suppurative  otitis  media  through 
antibiotics.  Hence  a  composite  study  on  the  mechanisms  of  antibiotic 
resistance is mandatory to formulate antibiotic policies for controlling multi drug 
resistant infections.
Against  this  background an attempt  was made for  ESBL production, 
inducibility of beta lactamases and isolation of plasmids in multidrug resistant 
pseudomonas  aeruginosa  isolates  from  chronic  suppurative  otitis  media. 
Patients attending ENT OP Coimbatore medical college hospital Coimbatore 
from October 2005 to September 2006. The importance of study lies in two 
reasons.
1. Pseudomonas aeruginosa is the commonest gram negative organism 
isolated from chronic suppurative otitis media .
2. The main mode of resistance of pseudomonas aeruginosa is through 
production of beta lactamases which is mainly plasmid mediated.
A  total  of  110  Specimens  collected  and  processed  from  chronic 
suppurative otitios media and 114 organisms were isolated. In which 9 patients 
had  more  than  one  organisms,  rest  of  the  patients  had  only  one  type  of 
organism.  Pseudomonas  aeruginosa  were  isolated  from  43  patients. 
Pseudomonas aeruginosa is the commonest organism isolated from chronic 
suppurative otitis media (Berry S etal: 1996, Samiullah et al: 2005). About 43 
(37.7%) pseudomonas aeruginosa were isolated in our study.
Patients  from  all  age  groups  were  included  in  this  study  .It  was 
observed that pseudomonas aeruginosa has been isolated from all age groups 
but increased isolation was seen in the age group of 21-30 (41.8%). This may 
be due to the population wise they are high in overall population and having 
the habit of taking bath in ponds, wells, water falls, swimming pools and also 
having the habits of introducing foreign bodies like match sticks, bird feather 
and safety pin in the ear.
 In our study we noted multidrug resistance is more commonly seen in 
pseudomonas  aeruginosa  23  (53.48%)  than  staphycococcus  aereus  12 
(32.4%), Klebsiella sp 3 (33.3%), proteus sp 2 (14.3%) The antibiogram profile 
pseudomonas  aeruginosa  have  showed  high  resistance  among  antibiotics 
Gentamicin 53.5% Tobramicin 53.5%, Ciprofloxacin 53.5%, Ofloxacin 53.5%, 
Cefotaxime 53.5%,  and high sensitivity among antibiotics Amikacin 79.1% , 
Ceftazidime 88.4%, Cefepime 86%, Meropenam 93%, Piperacillin 95.34% By 
considering  Antibiogram  profile  of  pseudomonas  aeruginosa  it  may  be 
suggested  the  first  line  of  treatment  for  multidrug  resistant  pseudomonas 
aeruginosa  is   Amikacin  or  Ceftazidime  or  Cefepime  and  Second  line  of 
treatment is meropenam or piperacillin,   Multidrug resistance pseudomonas 
aeruginosa infection was most commonly seen in the age group of more than 
50 years. This may be due to that immunity to infections will  be less when 
compared  to  other  age  group  and  hence  this  increased  prevalence  rate. 
Similar findings were observed by samiullah et al; 2005. 
There is no significant sex predilection observed when the entire study 
was  considered  .However  when  the  occupation  was  analyzed  most  of  the 
patients were agricultural workers, who account for 38.8% of the study group. 
Pseudomonas aeruginosa is a widely prevalent ubiquitous organisms in nature 
hence agricultural workers are commonly affected. The office going and house 
wife group were the least affecting groups.
In the present study it was observed that 11.6% of strains were resistant 
to  ceftazidime  and  53.5%  of  strains  were  resistant  to  cefotaxime.  Bouza 
observed  a  similar  findings  in  his  study  where  15%  of  the  strains  of 
pseudomonas aeruginosa were resistant to ceftazidime In the present study, 
antibiogram showed that  53.5% of  the  strains were  resistant  to  cefotaxime 
.Robert had reported that 46% of the pseudomonas aeruginosa strains were 
resistant  to  cefotaxime .Resistant  to  ciprofloxacin  was  observed  for  53.5% 
when compared with other Indian studies the resistance is high in our study. 
Inducibility of beta lactamases among strains sensitive to cephalosorin 
was detected using double disc diffusion method as described by Miles(Miles ,  
1996) The induction of beta lactamases was seen in 40% of isolates by using 
an approximation of 25 mm disc distances (Qin, et al; 2004; Miles ,1996).This 
rate is low when compared to the earlier observation made by Mortiz (Mortiz 
and Carson.,1996)  who had demonstrated 68% of  induction for  cefotaxime 
using disc approximation method .But we could induce for all  100% strains 
after decreasing the distance between cefoxitin and cefotaxime by 5 mm.
This  inducibility  is  significant  because  different  beta  lactamases  are 
induced  at  different  disc  approximations,  hence  by  decreasing  the  disc 
distance we may induce different type of betalactamases, there by proving the 
capacity  of  individual  strains  to  induce  these  enzymes  for  producing  drug 
resistance.
A similar method was followed for detecting the presence of extended 
spectrum  betalactamases  among  resistant  strains.  By  standard  disc 
approximation method (25mm) we could detect ESBLs in one strain ,but by 
reducing disc distances we could show the presence of ESBLs in 78.2% of the 
strains.  There  are  more  than  192  types  of  betalactamases  are  discovered 
(Bradford,  2001).These  betalactamases  were  produced  at  different 
concentration gradients of antibiotics (Bert et al.,2003 ) . Some of them are 
produced even at low level of selective pressure produced by these antibiotics 
and some (require high antibiotic concentration for producing betalactamases. 
By altering the distances we can vary the concentrations and in turn 
vary selective pressures of antibiotics to pseudomonas aeruginosa. This may 
be  possible  reason  for  more  strains  producing  ESBLs  at  reduced  disc 
approximations According to Bert et al, the standard test with 30 mm distance 
is insufficient to identify most ESBLs produced by pseudomonas sp (Bert et al.,  
2003).  Strains  produced  only  TEM  derived  enzymes  and  one  PER-1were 
detected by use of a 30 mm distance .It was necessary to reduce the distance 
to 20 mm to detect strains that produce VEB -1 ,SHV29 and OXA 18 .Where 
as strains that produce the other OXA derived ESBLs were identified only at a 
distance of 10 or15 mm .In the present study it was not possible to detect the 
types  of  ESBLs  produced,  as  it  may  require  molecular  type  methods  .By 
further expanding the scope of this study ,it is possible to typing these ESBLs 
with the help of molecular methods and identifying the  gene responsible for 
the resistance can be detected. 
In this study synergy between cephalosporins and aminoglycosides and 
cephalosporins and flouroquinolones was detected by disc diffusion method 
based on Kirby -Bauer' s antibiotic susceptibility testing as done by Mayer and 
Nagy  (Mayer  and  Nagy,  1999).The  synergy  effect  of  ceftazidime  with 
aminoglycoside was seen against 53.5% and the synergic effect of ceftazidime 
with flouroquinolones was seen against 50.1% of strains. These combinations 
may  be  useful  in  treating  the  patients  with  pseudomonas  aeruginosa  but 
cephalosporin aminoglycoside combination is found to be more nephrotoxic 
than drugs used as monotherapeutic agents.
 When  combination  of  cefotaxime  with  aminoglycoside  and 
flouroquinolones were tested against pseudomonas aeruginosa drug synergy 
was observed in 48.8 % and 48.8 respectively.  Though in this study synergy 
was  detected  with  disc  diffusion  test.  Measurement  of  time  killing  of  the 
bacteria is the most means of assessing existence synergic effect between 
drugs (Mayer and Nagy).
Resistant plasmid isolation was done in all ESBL possitive strains (23) 
by alkaline lysis method developed by Birnboim and Doly. It was observed that  
plasmids were present all  ESBL positive strains, which may be indicative of 
resistant plasmid.
In  conclusion  pseudomonas  aeruginosa  can  be  agreed  upon  as  the 
most  dreaded  Gram  negative  bacteria  among  isolates  from  chronic 
suppurative otitis media The main mode of resistance among these organisms 
is through beta lactamase and all the strains can be induced to produce beta 
lactamases . Through this study we detected ESBLs and plasmid among the 
multi  drug  resistant  strains  all  the  multidrug  resistant  pseudomonas 
aeruginosa.  Further  research  on  type’s  structure  and  genetic  basis  for 
production ESBL will definitely be an important improvement, which will surely 
have  a  major  bearing  on  treatment.  All  the  ESBL  producing  strains  being 
sensitive to cephalosporins and sulbactum combination.
This study from October 2005 to September 2006 revealed that 53.5 
percent  of  pseudomonas  aeruginosa  isolates  from  CSOM  were  multidrug 
resistant.  This  study  showed  CSOM  infections  are  commonly  due 
pseudomonas  aeruginosa  and  staphylococcus   aureus.  How  ever 
pseudomonas aeruginosa is associated with high level of drug resistance to 
common  antimicrobial  agents.  Ie  Gentamicin,  Tobramycin  ciprofloxacin, 
ofloxacin,  cefotaxime,  (Jacoby  GA  et  al.  1991).  Drug  resistance  in 
pseudomonas aeruginosa is alarming; therefore, Antimicrobial Agents must be 
selected according to local sensitivity studies. Enzymes mediated resistance of 
pseudomonas  aeruginosa  can  be  attributed  not  only  to  an  inducible, 
chromosomally  mediated  β  –Lactamase   that  can  render  broad  spectrum 
antibiotics inactive and it has plasmid mediated β – Lactamase hydrolysis. A 
major factor that has lead to the increase in antimicrobial resistant strains has 
been  wide  spread use  of  broad spectrum drugs  including  the  use of  third 
generation cephalosporins and fluoroquinolones. The challenge for physician 
and  Surgeon  in  to  develop  stricter  pathogen  surveillance  and  drug 
susceptibility testing and to follow Judicious utilisation of both older and newer 
antimicrobial agents.
Cefepime  has  greater  stability  against  SHV  type  enzymes  (ESBL) 
expressed  by  enterobacteriacae  and  has  greater  activity  against  strain 
producing these enzymes than other cephalosporins.
Resistance to antimicrobial agents is an increasing public health threat. 
It  limits  therapeutic  options and leads  to  increased morbidity  and  mortality 
(NNISS  data  summary  2004)  given  the  increasing  rate  in  pseudomonas 
aeruginosa,  multidrug  resistance  more  prevalent  among  CSOM  patients 
attending  hospitals  (or)  community.  More  over  the  intensity  of  selection 
pressure by broad spectrum antibiotics in high in ENT Department. Treatment 
with  multiple  antibiotic  agents  for  other  resistant  organisms  and  treatment 
broad  spectrum  cephalesporins  and  aminoglycosides  specifically  also 
emerged as being important risk factors (Gould I.M. et al; 1994). Infection with 
MDR pseudomonas aeruginosa in associated with adverse clinical out come, 
and strict isolation of patients with MDR micro organisms and Judicial use of 
antibiotic  should  be  emphasised  in  order  to  prevent  the  spread  of  MDR 
pseudomonas aeruginosa.  The emergence and spread of antibiotic resistant 
bacteria and describes research and development aimed at controlling these 
organisms.  It  concludes  that  efforts  are  necessary  both  to  preserve  the 
effectiveness of currently available antibiotics and develop new antibiotics.
Antibiotic  creates  “Selective  Pressure  “that  promotes  the  spread  of 
resistant  bacteria.  Susceptible  bacteria  are  killed  or  inhibited  and  resistant 
bacteria  survive  and  multiply,  as  bacteria  become  resistant  to  increasing 
numbers of antibiotics are used more often increasing the selection pressure 
for bacteria to become resistant to them. The report identified hand washing, 
improved hygiene and patient isolation as successful infection control efforts.
Finally we can conclude that we should give at the most importance to 
study  the  multidrug  resistance  mechanisms  of  pseudomonas  aeruginosa. 
Other wise we will face a severe threat from these MDR infectious organisms. 
So continuous surveillance and research works is mandatory to combat the 
multidrug resistant infections.
Summary
• 110 Specimens were collected from 100 CSOM patients attending ENT 
op at Government Medical College Hospital, Coimbatore during October 
2005 to September 2006.
• 43 strains of pseudomonas aeruginosa were collected during the study 
period.
• Antibiotic  susceptibility  testing  was  done  for  these  strains  by  Kirby 
-Bauer disc diffusion method. 
• MIC for all 43 strains were detected using Hicomb test (E-TEST).
• Antibiotic  susceptibility  of  the  strains  were  correlated  with  their  MIC 
value.
• Inducibility of beta lactamases were detected for the 20 sensitive trains 
isolated, by double disc diffusion test and it was observed that all 20 
strains  were  induced  to  produce  betalactamases  with  disc 
approximation at 20 mm apart. Only 8(40%) were induced to produce 
betalactamases when the discs were 25 mm apart.
• ESBLs were detected for the resistance strains by double disc diffusion 
test. Presence of ESBL was detected in 4.3 % strains through 20mm 
disc  approximation,  34.7%  of  strains  through  15mm  of  disc 
approximation, 78.2% through 10 mm disc approximation.
• The synergic effect between 
Cephalosporins and  aminoglycoside
Cephalosporins and flouroquinolones
Were detected using double disc diffusion method .It was observed that 
synergy  between  aminoglycoside  and  cephalosporins  was  found  to  be 
maximum 53.5%        :
• Plasmid  profile  analysis  was  done  for  all  ESBL  positive  strains  and 
plasmids were detected in all ESBL positive strains.
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Master Chart
MASTER CHART – ABBREVIATION
PA – Pseudomonas Aeruginosa
Kle – Klebsiella sp
Sa – Staphylococcus aureuss
Pro – Proteus Sp
Str - Streptococcus pyogens
Es. Coli - Escherichia Coli
Mx - Moraxella Catarrhalis
Cons - Coagulase negative staphylococcus aureus
A - Asperigillus sp
C - Candida sp
Occuption
1. Agri
2. Construction worker
3. Pre – School
4. School
5. College
6. Employee
7. House wife
8. Others
Oc - Occupation
CF - Clinical Features
ED - Ear Discharge
HoH -  Hard of hearing
URTI - upper Respiratory Tract Infection
CSOM - Chronic Suppurative Otitis Media
GNB - Gram Negative Bacilli
GPC - Gram Positive Cocci
O -  Other organisms
SDA - Sabouraud;s Dextrose Agar
BAP - Blood Agar Plate
CET - Cetrimide Agar
CA - Choclate Agar
MAC - Macconkey Agar
M - Male
F - Female
MOT - Motility test
NA42/Pig  - Growth at 42 ºC in Nutrient Agar/Pigmentation.
NLF - Non Lactose Fermenter.
LF - Lactose Fermenter
MLF - Minute Lactose Fermenter
LFM - Lactose Fermenter mucoid
Mix - Mixed
C - Catalase
OX - Oxidase
SFT - Sugar Fermentation Test
OFT - Oxidation. Fermentation Test
AK - Amikacin
CIP - Ciprofloxacin
CEF - Cefotaxime
CTZ - Ceftazidime
MERO - Meropenam
MDR - Multidrug resistant
SYN - Synergic Test
MIC - Minimum Inhibitory concentration
IND β L - Inducible β – Lactamase
ESBL - Extend Spectrum of β – Lactamase.
S - Sensitive
R - Resistant
E - Effective
W - Weak
AST - Antibiotic Sensitivity test.
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1. Veeramuthu 19 M 25737 8 + - + Lt + - - + - - NLF - + + + + + - O PA S S S S S - E 3 0.5 +
2. Rajendiran 40 M 25905 8 + + - Rt + - - + - - NLF - - - + + - + F Pro S S S S S -
3. Manjula 11 F 25901 4 + + - Rt + - - + - - NLF - + + + + + - O PA S R R S S + E 64 5 + +
4. Sadam Husain 12 M 25954 4 + - + Lt + - - + - - LF - - - - + - + F Kle S S S S S -
5. Rahim 29 M 26330 1 + + - Rt + - + NLF - + + + + + - O PA S R R S S + W 16 1 + +
Lt - - - - + - NLF - - - - + - + F SA S S S S S -
6. Rajendren 34 M 26623 2 + + - Lt + - - + - - MLF - + + + + + - O PA S S S S S - E 7.5 5 +
7. Sahisudheen 28 M 26730 1 + - + Rt + - - + - - NLF - - - - + - + F Kle S S S S S +
Lt + - - + - - LFM - + + + + + - O PA S S S S S - W 7.5 5
8. Renganathan 64 M 27113 8 + + - Rt - - - - - - - - - - - - - - - NG
9. Krishnan 53 M 27180 2 + + - Lt - - - - - - - - - - - - - - - NG
10. Balamurugan 29 M 27572 5 + - + Lt - - + - + + MLF + - - - + - + F SA+c S R R S S +
11. Ramakrishnan 30 M 27255 5 + + - Rt - - - - + - - - - - - - - + F Str S S S S S -
12. Chinnasamy 37 M 27556 1 + + - Lt - - - - + - MLF - - - - + - + F SA S S S S S -
13. Prakash 35 M 27679 2 + + + Lt + - - + + - M - - - + + + - O PA S S S S S - E 7.5 3 +
- + - + F SA S S S S S -
14. Priyadarshini 1½ F 28080 3 + + - Rt - - - - + - MLF - - - - + - + F SA S S S S S -
15. Kerjim 32 M 28076 8 + + + Rt + - - + - - NLF - - - + + - + F Pro S S S S S -
16. Palamvel 20 M 28127 5 + - + Lt - - - + + - MLF - - - - + - + F SA S S S S S -
17. Shreya 23 F 28153 5 + + + Lt - - - - - - - - - - - - - - - NG
18. Manickammal 60 F 28003 2 + - + Rt + - - - - - NLF A
S
+ + + + + - O PA+
AS
R R R R R + W 240 120 + +
19. Senthil Kumar 30 M 28244 1 + + + Rt - - - + + - - - - - - - - + F Cons S S S S S -
+ Lt - - - + + - MLF - - - - + - + F SA S S S S S -
20. ISSAN 4 M 28267 4 + + - Rt + - - + + - Mix - - + + + + - O PA S R R S S + 10 1 + +
- - - - + - + F SA R R R R R +
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21. Subramani 44 M 28285 5 + + - Lt + - - + - - NlF - + + + + + - O PA S S S S S - E 7.5 1 +
22. Babu 46 M 28288 8 + - - Rt - + - + - - NLF - - - - + - + F SA S S S S S -
23. Priya 20 F 28431 4 + + + Lt + - - + + - MLF - - - - + - + F Pro S S S S S -
24. Ahamedshan 63 M 28364 2
+
- + Lt - + - - - + NLF + - - - + - + F SA+
c
S R R S S -
25. Azhandheen 11 M 28419 4 + + - Rt - + - - - - MLF - - - - + - + F SA S S S S S +
26. Manikandan 25 M 28444 1 + + + Lt + - - + - - NLF - + + + + + - O PA S R R S S + 3.2 5 - + +
27. Kumarasamy 32 M 28365 2 + - + Lt + - - + - - LFM - - - - + - + F Kle S S S S S -
28. Praveen kumar 13 M 28571 4 + + - Lt + - - + - - NLF - + + + + + - O PA S S S S S - E 5 0.5 +
29. Viapuri 65 M 28666 8 + + - Lt + - - + - - NLF - - + + + + - O PA R R R S S + 16 1 + +
30. Ravikumar 23 M 28700 5 + + - Lt - - - - - - - - + - - - - - - NG
31. Karuppasamy 54 M 19382 2 + + - Rt - + - - - - MLF - + - - + - + F SA S S S S S
32. Subhiksha 42 F 18990 7 + + - Rt + - + - + - LF - - - - + - + F Kle S R R S S +
33. Paridha 22 F 18616 5 + - + Rt + - - - + - NLF - - + + + + - O PA S R R S S + W 60 3 + +
34. Emilini 23 F 18660 5 + + - Lt - + - - + - MLF - - - - + - + F SA S S S S S -
35. Lakshmi 27 F 18413 6 + + - Lt - + - + + - MLF - + - - + - + F SA S S S S S - E 7.5 3 +
36. Karthikeyan 17 M 17700 5 + + - Lt - + - + - - MLF - - - - + - + F SA S S S S S +
37. Amsagiri 8 M 17582 1 + + - Rt + - - - + - NLF - - + + + + - O PA S S S S S -
38. Myrose 56 F 17339 4 + - + Rt + - - + - - LFM - - - - + - + F Kle S S S S S -
39. Santhosh 45 M 17585 4 + + - Lt - + - + + - MLF - + - - + - + F SA S S S S S -
40. Ramani 17 M 17373 8
+
+ - Rt + - - - - - Mix - - - - + - + F SA+
c
S S S S S -
Lt - + - - + - - - - - - - + F Cons S S S S S -
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41. Bhackiyam 16 M 17417 6 + + - Lt + - - - - - NLF - - + + + + - O PA R R R R R + W 240 120 + +
42. Vijayalakshmi 13 F 16776 4 + - - Lt - - - - - - - - - - - - - - - NG S S S S S -
43. Nithya 26 F 16502 4 + + - Lt + - - + + - NLF - + - + + - + F Pro S S S S S -
44. Nandhini 35 F 16520 4 + - - Rt + - - + + - NLF - - - + + - + F Pro S R R S S +
45. Gowri 42 F 16379 1 + + - Lt + - - - + - NLF - - + + + + - O PA S R R S S + 32 1 + +
Rt - - - - + - - - + + - + F SA S S S S S -
46. Pappammal 24 F 2856 2 + + + Rt + - - + + - NLF - + + + + + - O PA R R R R R + 32 16 + +
47. Gandhi mathi 35 F 7939 1 + + - Rt - - - + - - MLF - - - - + - + F SA S S S S S
48. Pappathy 35 F 19955 1 + + - Rt + - - - + - NLF - - + + + + +- O PA S S S S S -
49. Sasikala 28 M 20682 1 + + - Rt + - - + - - NLF - + + + + + - O PA S S S S S - 7.5 5 +
50. Dhanalakshmi 63 F 12114 7 + + - Lt + - - + - - NLF - + + + + + - O PA S R R S S + 16 5 + +
51. Gopinath 8 M 20694 4 + - + Lt - + - - + - MLF - - - - + - + F SA S S S S S -
52. Sundari 40 F 22667 1 + - - Rt + - - + - - NLF - + + + + + - O PA S R R S S + 120 2 + +
53. Gopalkrishna
n
63 M 85472 8 + + - Rt + - - + - - NLF - - + + + + - O PA R R R S S + 32 3 + +
Lt - + - - + - MLF - - - - + - + F SA R R R R R +
54. Santhi 28 F 2599 7
+
+ - Lt - - - - - - - - - - - - - + F CON
S
S S S S S -
55. Britto 3 M 28419 3 + - - Rt + - - + - - NLF - + + + + + - O PA S S S S S - E 7.5 2 +
Lt - - + - - + Mx S S S S S -
56. Afna 4 F 29731 3 + - - Lt - + - - + - MLF - - - - + - + F SA S S S S S -
57. Vinoth 9 M 1679 4 + + - Rt + - - + - - NLF - + + + + + - O PA S S S S S - W 5 1 +
Lt + - - + - - NLF - - - + + - + F PRO S S S S S -
58. Veerammal 29 F 1738 1 + - + Lt + - - + - - NLF - + + + + + - O PA S R R S S + 16 1 + +
59. Kalai vani 32 F 1784 6
+
- + Lt - + - - + - MLF + - - - + - + F SA+
c
R R S S S +
60. kannan 10 M 1786 4 + - - Lt + - - + - - NLF - + + + + + - O PA S R R S S + 32 1 + +
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61. Malaevili 5 F 36745 4 + + - Lt - + - - + - MLF - - - - + - + F SA S R R R S +
62. Sundharapandi 30 M 37192 6 + + - Rt - + - - + - MLF - - - - + - + F SA S S S S S -
Lt + - - + - - NLF - + + + + + - O PA S S S S S - 7.5 5 +
63. Dowlath 34 F 39318 7 + - - Rt + - - + - - NLF - - - + + - + F PRO S S S S S -
64. Banu 16 F 2041 4 + - - Rt + - - + - - NLF - + + + + + - O PA S R R S S + 240 10 + +
Lt - + - - + - MLF - - - - + - + F SA S R R S S +
65. Kavitha 25 F 2304 1 + + - Lt + - - + - - NLF - + + + + + - O PA R R R R R + 60 16 + +
66. Ranju 40 F 2524 2 + + - Rt + - - + - - NLF - + + + + + - O PA S S S S S - W 3 0.5 + -
67. Jeyanthi 31 F 2557 6 + - + Rt - + - - + - MLF - - - - - - + F SA S S S S S -
68. Backiyam 45 F 2689 6 + - + Lt + - - + - - NLF - - - + + - + F PRO S S S S S -
69. Chandra 20 F 2296 5 + - - Lt + - - + - - LFM - - - - + - + F Kle S S S S S -
70. Dhanasekar 14 M 2813 4 + + - Lt - + - - + - MLF - - - - + - + F SA S R R S S +
71. Duraiammal 26 F 3063 1 + + - Rt + - - + - - NLF - + + + + + - O PA S S S S S - E 5 0.5 +
72. Meghala 25 F 3072 5 + - + Lt + - - + - - NLF - - - + + - + F PRO S S S S S -
73. Parameswari 25 F 3202 7 + + - Rt + - - + - - NLF - + + + + + - O PA S S S S S - E 4 0.5 +
74. Kannammal 27 F 3211 6 + + - Rt + - - + - - NLF - + + + + + - F PA S S S S S - E 3 1 +
75. Lakshmi 25 F 3242 6 + - - Lt + - - + - - LFM - - - - + - + F Kle R R R R R +
76. Fathima 29 F 3696 1 + - - Lt + - - + - - NLF - + + + + + - O PA R S S R S + 7.5 60 + +
77. Marimuthu 4 M 4332 3 + - - Lt - + - - + - MLF - - - - + - + F SA S S S S S -
78. Prasanna 8 M 4430 4 + + - Rt - + - - + - MLF - - - - + - + F SA S S S S S -
79. Jaya 24 F 4485 5 + - + Rt + - - + - - NLF - + + + + + - O PA S S S S S - E 7.5 2 +
80. Mangattha 37 F 4492 6 + + - Rt - + - - + - MLF - - - - + - + F SA S R R R S +
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